Stereotactic Radiosurgery for Brain Metastasis
What You Need to Know Before You Apply
What is the purpose of this trial?
This phase II trial compares the effect of single fraction stereotactic radiosurgery to fractionated stereotactic radiosurgery for the treatment of patients with cancer that has spread to the brain (metastatic brain disease). Stereotactic radiosurgery (SRS) is a form of radiation therapy that focuses high-power energy on a small area of the body. This trial is being done to determine if single (one) fraction stereotactic radiosurgery is better than fractionated stereotactic radiosurgery or vice versa in controlling tumor and side effects in patients with tumors that have spread to the brain.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is stereotactic radiosurgery (SRS) safe for treating brain metastases?
How is stereotactic radiosurgery different from other treatments for brain metastasis?
Stereotactic radiosurgery (SRS) is unique because it delivers a single, highly focused dose of radiation directly to the brain metastasis, minimizing damage to surrounding healthy tissue. Unlike whole brain radiation therapy, which affects the entire brain, SRS targets only the tumor, making it a precise and less invasive option.678910
What data supports the effectiveness of the treatment Stereotactic Radiosurgery for brain metastasis?
Research shows that Stereotactic Radiosurgery (SRS) can prolong survival in patients with a single brain metastasis and maintain functional independence in those with up to three brain metastases. Additionally, SRS, specifically CyberKnife Radiosurgery, has been effective in managing brain metastases based on total tumor volume, offering a precise and localized treatment option.47111213
Who Is on the Research Team?
Paul D. Brown, M.D.
Principal Investigator
Mayo Clinic in Rochester
Are You a Good Fit for This Trial?
This trial is for adults with cancer that has spread to the brain from another body part, like lung or breast. Participants must have at least one tumor in the brain between 2.0 and 4.0 cm not previously treated with radiosurgery, be able to undergo MRI scans, and have a certain level of physical function (KPS >= 50 or ECOG PS >= 2). Pregnant women and those who've had whole-brain radiation or specific large brainstem metastases are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo either single fraction SRS or fractionated SRS
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Stereotactic Radiosurgery
Stereotactic Radiosurgery is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Cancer Institute (NCI)
Collaborator